The Internet Of Medical Things: 6 Stocks In Focus
Zacks Investment Research | Sep 25, 2016 09:33PM ET
The Internet of Medical Things (IoMT) is fast gaining pace as pharma companies look to innovate and keep up with technology to help patients and physicians better monitor and track diseases. With a couple of deals being announced this month, IoMT seems like the future of healthcare.
IoMT – A Healthcare Revolution
IoMT involves the bringing together of technology and medical devices and applications. Chronic diseases which require frequent monitoring can be tracked effectively so that patients receive timely and proper treatment. It is already a part of our daily lives in the form of wearable devices like Apple (NASDAQ:AAPL) Watch, Fitbit and Samsung (KS:005930) S Health which help users achieve their fitness and health targets.
Pharma and tech companies are now taking things a step further and are collaborating to make devices that can track chronic and lifestyle associated diseases like diabetes which are growing at a fast pace.
In fact, the scope for innovation in this area is endless -- contact lenses that can detect glucose levels, a device that can monitor caloric intake, bioelectronic medicines that can tackle and maybe treat a wide range of chronic diseases, robotic-assisted surgery – all these are actually some of the widely interesting areas covered by IoMT.
As more deals between pharma and tech companies get announced, it makes sense to take a look at some of the key players in this rapidly evolving area.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) signed up with Intel Corporation (NASDAQ:INTC) in mid-September to develop a wearable device and machine learning platform that can be used in Huntington disease (HD). Patients in an ongoing study will use a smartphone and wear a smartwatch equipped with sensing technology which will continuously monitor their general functioning and movement. The data will be wirelessly streamed to a cloud-based platform specifically developed by Intel to analyze data from wearable devices. The data will then be translated in near real-time into objective scores of motor symptom severity which in turn will help improve understanding regarding disease progression and the impact of treatment. Intel is a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
INTEL CORP Price and Consensus
TEVA PHARM ADR Quote
Another pharma-tech deal that made news this month is the joint venture (JV) between French drugmaker, Sanofi (PA:SASY) (NYSE:SNY) , and Verily Life Sciences, an Alphabet (NASDAQ:GOOGL) company. The JV, Onduo, will be focused on the development of comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management for diabetics. Sanofi’s expertise in diabetes will be combined with Verily’s experience in miniaturized electronics, analytics, and consumer software development.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.